Literature DB >> 3521691

Captopril and opiate antagonism in essential hypertension.

A A Ajayi, P C Rubin, J L Reid.   

Abstract

Six patients maintained on 50-100 mg captopril, for 2-25 months, were administered captopril 50 mg orally, together with either naloxone or 0.9% saline vehicle (placebo) given intravenously, in a double-blind crossover study. Naloxone did not appear to modify the circulatory effects of captopril in these patients, in contrast to earlier findings after acute captopril administration in normotensives. The results do not support an important endogenous opioid role in the chronic antihypertensive effect of captopril, but provide evidence that different mechanisms may contribute to the early short term falls in blood pressure, compared to the later long term effects.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3521691      PMCID: PMC1401039          DOI: 10.1111/j.1365-2125.1986.tb02840.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin.

Authors:  H Y Yang; E G Erdös; Y Levin
Journal:  Biochim Biophys Acta       Date:  1970-08-21

2.  Effect of age and high blood pressure on baroreflex sensitivity in man.

Authors:  B Gribbin; T G Pickering; P Sleight; R Peto
Journal:  Circ Res       Date:  1971-10       Impact factor: 17.367

3.  Use of first-dose response or plasma renin activity to predict the long-term effect of captopril: identification of triphasic pattern of blood pressure response.

Authors:  D B Case; S A Atlas; J H Laragh; P A Sullivan; J E Sealey
Journal:  J Cardiovasc Pharmacol       Date:  1980 Jul-Aug       Impact factor: 3.105

4.  Enkephalin as a transmitter for presynaptic inhibition in sympathetic ganglia.

Authors:  S Konishi; A Tsunoo; M Otsuka
Journal:  Nature       Date:  1981-11-05       Impact factor: 49.962

5.  Inhibition of in situ metabolism of [3H](met5)-enkephalin and potentiation of (met5)-enkephalin analgesia by captopril.

Authors:  S M Stine; H Y Yang; E Costa
Journal:  Brain Res       Date:  1980-04-21       Impact factor: 3.252

6.  Separation of human brain angiotensin-converting enzyme from enkephalin-degrading activity.

Authors:  A Arregui; C M Lee; P C Emson; L L Iversen
Journal:  Eur J Pharmacol       Date:  1979-10-26       Impact factor: 4.432

7.  Effect of angiotensin-converting enzyme inhibition on circulating and local kinin levels.

Authors:  C I Johnston; B H Clappison; W P Anderson; M Yasujima
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

8.  Vasodepressor property of the converting enzyme inhibitor captopril (SQ 14 225): the role of factors other than renin-angiotensin blockade in the rat.

Authors:  E S Marks; R F Bing; H Thurston; J D Swales
Journal:  Clin Sci (Lond)       Date:  1980-01       Impact factor: 6.124

9.  Effect of naloxone on the actions of captopril.

Authors:  A A Ajayi; B C Campbell; P C Rubin; J L Reid
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

10.  Captopril potentiates the vasodepressor action of Met-enkephalin in the anaesthetized rat.

Authors:  R Di Nicolantonio; J S Hutchinson; Y Takata; M Veroni
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

View more
  1 in total

1.  Naloxone does not antagonize the antihypertensive effect of chronic captopril therapy in hypertensive patients.

Authors:  G P Bernini; A R Lucarini; M S Vivaldi; C Del Corso; M Lenzi; A Salvetti
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.